<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> is a frequent feature of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) that could be improved by the use of recombinant human megakaryocyte growth and development factor (rHuMGDF) </plain></SENT>
<SENT sid="1" pm="."><plain>Using short-term liquid cultures and progenitor assays, we have found that rHuMGDF stimulated DNA synthesis and potentiated leukemic cluster growth of bone marrow mononuclear cells in 10/38 MDS cases (26%) </plain></SENT>
<SENT sid="2" pm="."><plain>Cytogenetically malignant colonies were detectable in rHuMGDF-stimulated cultures (n=3) by fluorescence in situ hybridization </plain></SENT>
<SENT sid="3" pm="."><plain>rHuMGDF was able to stimulate CFU-MK formation in 45% of the samples tested </plain></SENT>
<SENT sid="4" pm="."><plain>Finally, rHuMGDF-induced <z:e sem="disease" ids="C0549414" disease_type="Neoplastic Process" abbrv="">blast cell proliferation</z:e> correlated with elevated expression of c-MPL, previously identified as a bad prognosis factor in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>